Summit Therapeutics Inc.
SMMT
Pozycja w akcjach
#1684
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Cena akcji
$15.80
Ostatnia synchronizacja: 2026-10-21
Kapitalizacja rynkowa
$12.61B
Zmiana (1 dzień)
-1.78%
Zmiana (1 rok)
-17.52%
Kraj
US
Handel Summit Therapeutics Inc. (SMMT)
Kategoria
Healthcare
Historia ceny akcji dla Summit Therapeutics Inc. (SMMT)
Najwyższa cena zamknięcia: $16.35 dnia 2026-10-01
Najniższa cena zamknięcia: $11.32 dnia 2015-03-01
Najniższa cena zamknięcia: $11.32 dnia 2015-03-01
Historia cen akcji firmy Summit Therapeutics Inc. od 2015 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | -6.38% |
| 2025 | -2.36% |
| 2024 | 648.94% |
| 2023 | -27.28% |
| 2022 | -16.52% |
| 2021 | -23.50% |
| 2020 | 244.19% |
| 2019 | 23.13% |
| 2018 | -88.74% |
| 2017 | 19.67% |
| 2016 | -15.67% |
| 2015 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $525.12 | 23.14% |
US
|
|
| $237.61 | 784.95% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $887.75 | 9.04% |
NL
|
|
| $289.96 | 1.88% |
BE
|
